Has Michelle Dusenberry received payments from drug or device companies?

Yes. Drug and device makers reported $11,744 in general payments to Michelle Dusenberry across 515 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michelle Dusenberry did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michelle Dusenberry come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michelle Dusenberry

Family · Massillon, OHNPI 1568106797

Payments from drug & device makers

$11,744in general payments, 2019–2025

Across 515 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$1K
Merck$797
Incyte Corporation$706
AstraZeneca$510
E.r. Squibb & Sons, L.L.C.$467
Johnson & Johnson$460
plus $7K from 54 others

What the payments were for

Food & beverage$10,87193%
Education$8737%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	60	$1,111
Merck	42	$797
Incyte Corporation	24	$706
AstraZeneca(2 entities)	21	$510
E.r. Squibb & Sons, L.L.C.	20	$467
Johnson & Johnson(2 entities)	23	$460
Astellas Pharma US Inc	15	$456
Eisai Inc.	22	$439
Seagen Inc.	15	$407
Daiichi Sankyo Inc.	21	$385
Myriad Genetic Laboratories, Inc.	8	$322
Bristol Myers Squibb	16	$273
AVEO Pharmaceuticals, Inc.	10	$269
Lilly USA, LLC	13	$264
Sanofi	13	$240
AbbVie	11	$224
Exelixis Inc.	7	$223
Takeda Pharmaceuticals U.S.A., Inc.	10	$209
Stemline Therapeutics Inc.	10	$204
Sobi, Inc	5	$201
EMD Serono, Inc.	8	$192
Pfizer	9	$158
Genentech USA, Inc.	8	$155
Genmab U.S., Inc.	7	$135
Bayer	7	$133
Sumitomo Pharma America, Inc.	7	$133
Lucid Diagnostics Inc.	1	$125
Regeneron Healthcare Solutions, Inc.	6	$123
Taiho Oncology, Inc.	1	$121
Exact Sciences	1	$117
Mirati Therapeutics, Inc.	4	$117
Neurelis, Inc.	1	$104
Servier Pharmaceuticals LLC	5	$97
Morphosys, US Inc.	5	$95
Pharmacyclics LLC, An Abbvie Company	4	$93
Karyopharm Therapeutics Inc.	5	$91
Novo Nordisk	2	$91
Ipsen Biopharmaceuticals, Inc	5	$87
Pharmacosmos Therapeutics Inc.	4	$85
Octapharma USA, Inc.	4	$78
Puma Biotechnology, Inc.	5	$76
Deciphera Pharmaceuticals Inc.	4	$69
Alnylam Pharmaceuticals Inc.	1	$62
SK Life Science, Inc.	1	$60
Edwards Lifesciences	1	$60
Boehringer Ingelheim	3	$57
Axsome Therapeutics, Inc.	1	$52
Array Biopharma Inc	2	$49
Corcept Therapeutics	1	$49
Blueprint Medicines Corporation	2	$48
Rigel Pharmaceuticals, Inc.	3	$46
Gilead(2 entities)	3	$46
Beone Medicines USA, Inc.	2	$43
Pharmaessentia USA Corporation	2	$42
ADC Therapeutics America, Inc.	2	$42
Organon	2	$39
Tersera Therapeutics LLC	1	$39
Amgen	2	$34
Kyowa Kirin, Inc.	2	$33
Iovance Biotherapeutics, Inc.	2	$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,744 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	29	$17,305
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	150	$2,869
Fentanyl	21	$2,309
Anastrozole	118	$2,300
Ondansetron Hcl	43	$1,837
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	79	$1,716
Morphine Sulfate ErMorphine Sulfate	51	$1,316
Oxycodone Hcl	84	$1,154
Hydroxyurea	45	$1,037
Ondansetron OdtOndansetron	42	$914
Potassium Chloride	41	$761
Prochlorperazine Maleate	52	$659
Gabapentin	30	$372
Letrozole	26	$366
Acyclovir	35	$329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$158	$17,30529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Massillon

William ConwayMassillon$16K
Eileen FauldsLewis Center$991K
Leigh Ann PanschDayton$670K
Natalie BelliniMayfield Heights$582K
Kaitlyn LovettMontgomery$286K
Amy RossDayton$281K
Renee OttSandusky$179K
Megan MillerSpringfield$156K
George KnightCincinnati$130K
Jillian HuntCincinnati$116K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →